{
    "clinical_study": {
        "@rank": "134574", 
        "arm_group": {
            "arm_group_label": "Teriparatide and vibration", 
            "arm_group_type": "Experimental", 
            "description": "Experimental:   Teriparatide and vibration\nDrug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months\nDevice: Vibration 10 min/day for 12 months"
        }, 
        "brief_summary": {
            "textblock": "This extension study will only enroll individuals who have completed one year of treatment\n      in the parent protocol \"Effect of Teriparatide, Vibration and the Combination on Bone Mass\n      and Bone Architecture in Chronic Spinal Cord Injury (NCT01225055)\". This study will allow\n      those individuals who received Teriparatide (20ug/day) and vibration (10 min/day) during the\n      parent study to be treated for a second year and will allow those individuals who received\n      teriparatide-placebo to have the opportunity to have a full year of teriparatide therapy.\n      This study will determine if two years of exposure to teriparatide will result in a greater\n      increase in Bone Mass Density (BMD) than that seen after a single year's treatment. Subjects\n      will be evaluated at 6 and 12 months after initiating treatment with measurement of bone\n      density as well as bone markers of formation and resorption."
        }, 
        "brief_title": "12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Spinal Cord Injury", 
            "Bone Loss", 
            "Osteoporosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Osteoporosis", 
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Enrollment in, and completion of one year of treatment, in protocol \"Effect of\n             Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in\n             Chronic Spinal Cord Injury\".\n\n          -  Adherence rate for teriparatide use of \u226560%.\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry, for\n             the duration of study participation, and for 90 days following completion of therapy.\n             Should a woman become pregnant or suspect she is pregnant while participating in this\n             study, she should inform her treating physician immediately.\n\n          -  A female of child-bearing potential is any woman (regardless of sexual orientation,\n             having undergone a tubal ligation, or remaining celibate by choice) who meets the\n             following criteria:\n\n               -  Has not undergone a hysterectomy or bilateral oophorectomy; or\n\n               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,\n                  has had menses at any time in the preceding 12 consecutive months).\n\n          -  Ability to understand and the willingness to sign a written informed consent.\n\n        Exclusion Criteria:\n\n          -  Individuals who could not tolerate teriparatide treatment.\n\n          -  Individuals who will not be able to return for all study visits.\n\n          -  Patients may not be receiving any other investigational agents.\n\n          -  Other medical conditions that in the opinion of the investigator would preclude the\n             subject from completing the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02025179", 
            "org_study_id": "A1195"
        }, 
        "intervention": [
            {
                "arm_group_label": "Teriparatide and vibration", 
                "description": "Teriparatide 20 ug daily Sub-Q over 12 months", 
                "intervention_name": "Teriparatide", 
                "intervention_type": "Drug", 
                "other_name": "Forteo"
            }, 
            {
                "arm_group_label": "Teriparatide and vibration", 
                "description": "Vibration 10 min/day for 12 months", 
                "intervention_name": "Vibration", 
                "intervention_type": "Device", 
                "other_name": "Soloflex WBV platorm"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Teriparatide", 
                "Bone Density Conservation Agents", 
                "Physiological Effects of Drugs"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Teriparatide", 
            "Osteoporosis", 
            "Spinal Cord Injury", 
            "Bone Diseases", 
            "Metabolic Bone Diseases", 
            "Musculoskeletal Diseases", 
            "Spinal Cord Diseases", 
            "Central Nervous System Diseases", 
            "Nervous System Diseases", 
            "Nervous System", 
            "Wounds and Injuries", 
            "Bone Density Conservation Agents", 
            "Physiological Effects of Drugs", 
            "Pharmacologic Actions", 
            "Vibration"
        ], 
        "lastchanged_date": "December 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611"
                }, 
                "name": "Northwestern University Feinberg School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "12 Month Open-Label Extension Study of the Effect of Teriparatide on Bone in People With Chronic SCI", 
        "overall_official": {
            "affiliation": "Northwestern University", 
            "last_name": "Thomas J Schnitzer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine if a second year of teriparatide treatment will result in an increase in BMD compared to baseline BMD values in people with chronic SCI.", 
            "measure": "Bone Mass Density (BMD)", 
            "safety_issue": "No", 
            "time_frame": "6 and 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02025179"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Northwestern University", 
            "investigator_full_name": "Thomas J. Schnitzer", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To determine the effects of continued teriparatide on serum markers of bone metabolism", 
            "measure": "Serum markers of bone metabolism", 
            "safety_issue": "No", 
            "time_frame": "6 and 12 months"
        }, 
        "source": "Northwestern University", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Defense", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}